Proud to see our research being presented at #ASCO2026 as we continue our mission to transform cancer care through innovative blood-based testing.
We welcome the opportunity to connect with colleagues, collaborators, and new partners throughout #ASCO26.
#LiquidBiopsy#Adela
We're excited to announce two presentations at #ASCO25 demonstrating the ability of Adela's tissue-agnostic test for MRD Detection and Response Monitoring to predict progression and identify non-responders to immunotherapy in solid tumors.
prnewswire.com/news-releases…
Looking forward to engaging with the oncology community on how #liquidbiopsy and tissue-free approaches are advancing cancer detection and monitoring across the cancer continuum #ASCO26
If you’re attending, let’s connect.
#Oncology#Adela@ASCO@ConquerCancerFd@OncUpdates
Heading to Precision Med #TRICON in San Diego? Catch Partner Mara Aspinall at two key sessions:
📅 3/11 | 3:40 PM PT – Driving Innovation in Precision Medicine
📅 3/12 | 8:00 AM PT – Investing in Precision Medicine
More info: triconference.com/@TriConference
Heading to Precision Med #TRICON in San Diego? Catch Partner Mara Aspinall at two key sessions:
📅 3/11 | 3:40 PM PT – Driving Innovation in Precision Medicine
📅 3/12 | 8:00 AM PT – Investing in Precision Medicine
More info: triconference.com/@TriConference
Jensen Huang, speaking at PMWC to a room full of healthcare pioneers, “Biology is one of the hardest problems. I’ve always hoped that your industry would have the benefit of our industry.”
“Artificial intelligence is finding intelligence in the data that you have.”
Adela demonstrates in a clinical validation study published in The Annals of Oncology the ability to detect recurrence up to 15 months in advance of clinical presentation (mean 4.1 months). Detecting early relapse can contribute to improved outcomes by guiding early intervention.
Today we are celebrating a significant milestone for Adela: the simultaneous publication of our clinical validation study for our tissue-agnostic MRD test in Head & Neck cancer in @Annals_Oncology and its presentation at #ESMO24.
prnewswire.com/news-releases…
Exciting presentation at ESMO demonstrating Adela's ability to detect recurrence in Head & Neck Cancer patients up to 15 months in advance of imaging/clinical presentation with a mean lead time of 4.1 months. #precisiononcology
I'm excited to share ep. 1 of Closing Time is live! Tune in as @LisaA pitches her new startup to @Lux_Capital General Partner @deenashakir. Co-hosted with my longtime friend @halletecco, Closing Time gives a unique view into the exciting world of healthcare startups.
It’s an exciting day for #genomics#startups! I am thrilled to be launching Illumina Ventures Labs alongside the Illumina Ventures team to provide #founders with access to #capital, fully equipped genomics labs in the US and UK and support from experienced operators.
Announcing the launch of Illumina Ventures Labs! Building on the Illumina Accelerator program, it will operate & provide access to fully equipped #genomics labs in the US & UK, mentorship & seed 💵 to attract a broad range of genomics related #startups.
illuminaventures.com/resourc…
This is a great advancement in women's health. These new care plans combined with the Mirvie #RNA platform translates risk prediction into disease prevention and reduces complications from #preeclampsia.
#PrecisionHealth#PregnancyHealth